OncoZenge AB (publ) (STO:ONCOZ)

Sweden flag Sweden · Delayed Price · Currency is SEK
5.68
-0.10 (-1.73%)
Feb 11, 2026, 11:14 AM CET
Market Cap73.10M +3.8%
Revenue (ttm)2.78M +69,475.0%
Net Income-8.56M
EPS-0.72
Shares Out12.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,873
Average Volume31,069
Open5.67
Previous Close5.78
Day's Range5.67 - 5.98
52-Week Range3.72 - 10.28
Beta1.30
RSI53.23
Earnings DateFeb 18, 2026

About OncoZenge AB

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 1
Stock Exchange Nasdaq Stockholm
Ticker Symbol ONCOZ
Full Company Profile

Financial Performance

In 2024, OncoZenge AB's revenue was 1,000, a decrease of -66.67% compared to the previous year's 3,000. Losses were -8.69 million, -45.37% less than in 2023.

Financial Statements